RxDoctor Payments Data

Sara Doguet, MD

Family Medicine · Youngsville, LANPI 1396010690

Payments from drug & device makers

$3,494in general payments, 2019–2025

Across 220 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$339
  • Corium, LLC$238
  • AstraZeneca$174
  • Pfizer$144
  • Takeda Pharmaceuticals U.S.A., Inc.$105
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,494 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$75,908
Medicare patients
233
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide114$123,597
JardianceEmpagliflozin58$55,794
TrulicityDulaglutide35$52,694
FarxigaDapagliflozin Propanediol29$46,109
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$33,430
OzempicSemaglutide26$26,478
Tresiba Flextouch U-100Insulin Degludec22$24,372
LinzessLinaclotide26$21,668
TrintellixVortioxetine Hydrobromide24$18,806
Dexlansoprazole DrDexlansoprazole25$10,662
GlyxambiEmpagliflozin/Linagliptin12$9,988
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,077
Amlodipine-ValsartanAmlodipine Besylate/Valsartan19$3,066
Duloxetine Hcl128$2,750
Atorvastatin Calcium358$2,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$339$176,291149 claims
Boehringer IngelheimJardiance, Glyxambi$39$65,78270 claims
AstraZenecaFarxiga$174$46,10929 claims
GSKTrelegy Ellipta$96$33,43022 claims
Novo NordiskOzempic, Novolog$97$27,94042 claims
AbbVieLinzess, Synthroid, Armour Thyroid$1,394$25,28592 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$105$18,80624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Youngsville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →